ZNF575 Antibody

What is ZNF575 and where is it primarily expressed?

ZNF575 is a zinc-finger protein belonging to the ZNF family of transcription factors. Research has detected ZNF575 expression mainly in the brain and reproductive tissues, suggesting its functional importance may be concentrated in these regions . At the molecular level, ZNF575 has been observed to directly interact with promoter regions of genes involved in cell cycle regulation and apoptosis, most notably the p53 promoter .

How is ZNF575 protein detected in experimental settings?

ZNF575 protein detection typically employs antibody-based methods including Western blotting, immunohistochemistry (IHC), and immunocytochemistry. Western blot analysis reveals ZNF575 as a 27 kDa protein, consistent with its predicted molecular weight . For tissue samples, IHC staining protocols commonly use specific antibodies such as bs-13588R (Bioss) at 1:100 dilution with overnight incubation at 4°C . Multiple cell lines including Jurkat, MCF7, and HeLa have demonstrated detectable levels of ZNF575 expression, making them suitable models for in vitro studies .

What antibody options are available for ZNF575 detection in different experimental contexts?

Several ZNF575 antibodies are available targeting different epitopes:

When selecting an antibody, researchers should consider the specific application, target species, and whether epitope accessibility might be affected by experimental conditions.

What is the functional significance of ZNF575 in colorectal cancer (CRC)?

ZNF575 demonstrates significant tumor-suppressive properties in colorectal cancer. Ectopic expression of ZNF575 inhibits CRC cell proliferation, reduces colony formation capacity, and promotes apoptosis in vitro . In xenograft tumor models, ZNF575 overexpression impaired tumor growth by 63.6% in volume and 58.7% in weight for HCT116 tumors, and 60.9% in volume and 49.1% in weight for RKO tumors . These findings suggest ZNF575 may function as a tumor suppressor, with potential implications for therapeutic development.

What molecular mechanisms underlie ZNF575's anti-tumor effects?

RNA sequencing analysis of ZNF575-overexpressing cells revealed that ZNF575 upregulates 245 coding genes, including p53, PUMA, and BAK . Mechanistically, ZNF575 directly targets the p53 promoter, enhancing p53 transcription and subsequently activating downstream apoptotic pathways . Knockdown experiments using p53-targeted shRNA demonstrated that p53 is essential for ZNF575-mediated inhibition of CRC proliferation, as silencing p53 blocked the anti-tumor effects of ZNF575 . These findings establish a ZNF575-p53-apoptosis signaling axis as the primary mechanism behind ZNF575's tumor-suppressive function.

What are the recommended protocols for ZNF575 detection in tissue samples?

For optimal ZNF575 detection in paraffin-embedded tissues, researchers should follow this validated protocol:

• Deparaffinize and rehydrate tissue sections

• Perform antigen retrieval under high temperature and pressure for 3 minutes

• Block with goat serum (room temperature, 15 minutes)

• Wash three times with PBS

• Incubate with primary ZNF575 antibody (1:100, bs-13588R; Bioss) overnight at 4°C

• Incubate with appropriate secondary antibodies (room temperature, 2 hours)

• Develop with 3,3′-diaminobenzidine

• Counterstain nuclei with hematoxylin

Expression scoring can be performed using a standardized grading system (4: >40% positive cells; 3: 20-30%; 2: 10-20%; 1: 0-10%; 0: negative) .

How should researchers design experiments to investigate ZNF575 function in cell lines?

To effectively investigate ZNF575 function in cancer cell lines:

• Selection of appropriate cell models: CRC cell lines including DLD-1, HT-29, RKO, HCT116, and SW620 show significantly decreased ZNF575 expression compared to normal colon epithelial cells (HCoEpiC), making them suitable for overexpression studies .

• Genetic manipulation approaches: Lentivirus-based ZNF575 overexpression systems have proven effective for stable expression in low-expressing cell lines such as HCT116 and RKO .

• Functional assays:

  • Cell proliferation assays (e.g., MTT/CCK8)

  • Colony formation assays

  • Apoptosis detection (flow cytometry)

  • RNA sequencing for downstream pathway analysis

  • ChIP assays to determine direct DNA binding targets

• In vivo validation: Xenograft models using ZNF575-overexpressing cells provide critical validation of in vitro findings. TUNEL assays on tumor sections can confirm apoptotic effects .

What controls should be included when validating a new ZNF575 antibody?

When validating a new ZNF575 antibody, researchers should include:

• Positive controls: Cell lines with known ZNF575 expression (Jurkat, MCF7, HeLa)

• Negative controls:

  • Primary antibody omission

  • Isotype-matched control antibodies (e.g., rabbit IgG for rabbit-derived antibodies)

• Knockdown/knockout validation: Cells with ZNF575 silenced via siRNA/shRNA or CRISPR

• Peptide competition: Pre-incubation with immunizing peptide should abolish specific signals

• Cross-reactivity testing: If working with non-human samples, validate species cross-reactivity using appropriate tissue/cell samples

• Multiple detection methods: Confirm results using orthogonal methods (e.g., Western blot plus IHC/ICC)

How can researchers investigate ZNF575's transcriptional regulatory functions?

To elucidate ZNF575's role as a transcriptional regulator:

• Chromatin immunoprecipitation (ChIP) assays: Using Flag-tagged ZNF575 constructs, researchers can identify direct DNA binding targets. Previous studies confirmed ZNF575 binding to the p53 promoter using this approach .

• Luciferase reporter assays: These assays can quantify ZNF575's effect on target gene promoter activity. For p53 promoter analysis, transfection of Flag-ZNF575 in 293T cells demonstrated enhanced p53 promoter activity .

• RNA sequencing: Comparative transcriptome analysis between control and ZNF575-overexpressing cells can identify broader regulatory networks. This approach identified 245 upregulated genes in ZNF575-expressing cells .

• Protein-protein interaction studies: Co-immunoprecipitation experiments can identify potential co-factors that might modulate ZNF575's transcriptional activities.

• ATAC-seq or DNase-seq: These approaches can determine whether ZNF575 alters chromatin accessibility at target loci.

What approaches can resolve discrepancies in ZNF575 expression data across different tissue types?

When confronting contradictory ZNF575 expression data:

• Antibody validation: Different antibodies targeting distinct epitopes may yield varying results. Confirm specificity using multiple antibodies targeting different regions of ZNF575 .

• Transcript vs. protein analysis: Compare RNA-seq/qPCR data with protein-level data, as post-transcriptional regulation may cause discrepancies.

• Tissue microenvironment considerations: ZNF575 expression in tissues may be influenced by microenvironmental factors. Microdissection techniques can isolate specific cell populations from heterogeneous samples.

• Single-cell analysis: Single-cell RNA-seq can resolve cell type-specific expression patterns that might be masked in bulk tissue analysis.

• Epigenetic regulation assessment: Analyze methylation status of the ZNF575 gene, as its methylation has been reported to be influenced by factors such as antidepressant intake during pregnancy .

How can researchers effectively integrate ZNF575 findings into broader cancer pathway analyses?

To contextualize ZNF575 research within the broader cancer biology landscape:

• Pathway enrichment analysis: GO term and KEGG pathway analysis of ZNF575-regulated genes revealed associations with apoptosis, p53 signaling, and axon guidance pathways .

• Multi-omics integration: Combine transcriptomic data with proteomic and phosphoproteomic analyses to build comprehensive signaling network models.

• Clinical correlation studies: Analyze ZNF575 expression in relation to other established biomarkers. For example, tissues with high ZNF575 expression typically also display high p53 expression .

• Cancer subtypes stratification: Determine whether ZNF575's prognostic significance varies across molecular subtypes of colorectal or other cancers.

• Therapeutic response prediction: Investigate whether ZNF575 expression levels correlate with response to specific therapeutic regimens, particularly those targeting p53-related pathways.

What are common technical challenges when working with ZNF575 antibodies and how can they be addressed?

Researchers frequently encounter these challenges:

• Non-specific binding: Optimize blocking conditions (5% BSA or milk) and antibody concentrations through titration experiments. For the commonly used ZNF575 antibody bs-13588R (Bioss), a 1:100 dilution with overnight incubation at 4°C has proven effective .

• Low signal intensity: Enhance detection through signal amplification systems such as biotinylated secondary antibodies with streptavidin-HRP, or consider antibodies conjugated with fluorescent tags for applications requiring higher sensitivity .

• Background in IHC/ICC: Implement additional blocking steps (e.g., avidin/biotin blocking for biotin-based detection systems) and include detergents (0.1-0.3% Triton X-100) in washing buffers to reduce non-specific binding.

• Inconsistent results between applications: Some antibodies perform better in specific applications. For example, intracellular flow cytometry protocols for ZNF575 detection require careful optimization of permeabilization conditions .

• Cross-reactivity concerns: Select antibodies with validated specificity for your species of interest. Middle region-targeting antibodies often provide broader species reactivity but may show higher cross-reactivity with related proteins .